ProQR Therapeutics (PRQR) Upgraded by ValuEngine to Sell
ValuEngine upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a strong sell rating to a sell rating in a research report sent to investors on Friday morning.
Several other brokerages have also recently weighed in on PRQR. Zacks Investment Research cut ProQR Therapeutics from a hold rating to a sell rating in a research report on Wednesday, November 15th. Chardan Capital reiterated a neutral rating on shares of ProQR Therapeutics in a research report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $18.88.
Shares of ProQR Therapeutics (NASDAQ PRQR) opened at $3.30 on Friday. The stock has a market capitalization of $105.14, a price-to-earnings ratio of -1.69 and a beta of 0.46. The company has a debt-to-equity ratio of 0.13, a current ratio of 5.95 and a quick ratio of 6.72. ProQR Therapeutics has a one year low of $2.75 and a one year high of $6.90.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Nine Chapters Capital Management LLC purchased a new position in shares of ProQR Therapeutics in the third quarter valued at $133,000. Wells Fargo & Company MN grew its position in shares of ProQR Therapeutics by 212.6% in the third quarter. Wells Fargo & Company MN now owns 43,226 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 29,400 shares in the last quarter. Sabby Management LLC purchased a new position in shares of ProQR Therapeutics in the fourth quarter valued at $1,120,000. Sphera Funds Management LTD. grew its position in shares of ProQR Therapeutics by 60.6% in the third quarter. Sphera Funds Management LTD. now owns 530,000 shares of the biopharmaceutical company’s stock valued at $2,571,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Artal Group S.A. grew its position in shares of ProQR Therapeutics by 26.7% in the fourth quarter. Artal Group S.A. now owns 1,900,000 shares of the biopharmaceutical company’s stock valued at $6,128,000 after purchasing an additional 400,000 shares in the last quarter. Institutional investors own 33.00% of the company’s stock.
About ProQR Therapeutics
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.